Education
About Us
Working with TipRanks
Follow Us
Olympus Corp. (OCPNF)
OTHER OTC:OCPNF
OCPNF Stock Chart & Stats
$13.20
$0.00(0.00%)
At close: 4:00 PM EST
$13.20
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$8.42 - $15.24
Previous CloseN/A
Volume15.00
Average Volume (3M)38.00
Market Cap
$9.56B
Enterprise Value$1.57T
Total Cash (Recent Filing)$196.74B
Total Debt (Recent Filing)$237.82B
Price to Earnings (P/E)38.6
Beta0.42
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.06%
Share Statistics
EPS (TTM)0.08
Shares Outstanding1,114,485,700
10 Day Avg. Volume0
30 Day Avg. Volume38
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)2.96
Price to Sales (P/S)2.23
P/FCF Ratio15.43
Enterprise Value/Market Cap163.95
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit2.40
Enterprise Value/Ebitda7.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.4
Revenue Forecast (FY)$6.37B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross and operating margins indicate durable product differentiation and pricing power in endoscopy systems. Strong margins support reinvestment in R&D, fund service networks, and provide buffer against cyclical volume declines, preserving long-term cash generation.
Recurring, Installed-Base Revenue ModelA business model combining capital equipment plus recurring consumables and service creates predictable aftermarket revenue and higher lifetime customer value. Installed base-driven consumable sales and service contracts provide structural revenue resilience and higher margin annuity streams.
Improving Balance Sheet And Manageable LeverageA lower, improving debt-to-equity ratio and sizable equity give financial flexibility to fund product development and M&A, while a TTM ROE around 13% shows decent capital returns. Strengthening leverage reduces refinancing risk and supports long-term strategic moves.
Bears Say
Stalled Top-Line MomentumFlat TTM revenue despite a strong product portfolio suggests slower adoption or market saturation in key segments. Prolonged revenue stagnation can limit scaling of fixed-costs, reduce upside from consumables growth, and constrain R&D or commercial investments over months.
Uneven Cash Flow And FCF VolatilityMaterial swings in operating cash flow and free cash flow undermine predictable capital allocation. Volatility hampers consistent reinvestment, dividends or debt reduction plans and raises execution risk for multi-quarter initiatives, affecting durable financial stability.
Exposure To Procedure Volumes And Procurement CyclesReliance on hospital procedure volumes and tender-driven procurement creates structural revenue cyclicality and pricing pressure. Regulatory delays or competitive tender outcomes can reduce consumables and equipment demand, pressuring long-term revenue and margin sustainability.
Olympus News
OCPNF FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was $8.42 and its highest was $15.24 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is $9.56B.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is Aug 12, 2026 which is in 160 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on Feb 13, 2026. The company reported $0.084 earnings per share for the quarter, missing the consensus estimate of $0.151 by -$0.067.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Overvalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Annually dividend of $0.191 which represents an annual dividend yield of 1.06%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of $0.084 in its last earnings report, missing expectations of $0.151. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in OCPNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
OCPNF Company Deck
OCPNF Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a strong financial performance with significant revenue and profit growth, particularly in North America. However, the resignation of the CEO amid allegations and challenges in China and other markets posed notable concerns. The overall sentiment is balanced by robust operational achievements and strategic advancements, such as AI medical device approvals.View all OCPNF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
11.82% Mutual Funds
<0.01% Other Institutional Investors
76.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---